Antares Pharma Reports Third Quarter 2017 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Antares Pharma (ATRS) PT Lowered to $5 at Jefferies
November 8, 2017 8:44 AM ESTJefferies lowered its price target on Antares Pharma (NASDAQ: ATRS) to $5.00 (from $6.00) while maintaining a Buy rating.
Analyst Anthony Petrone notes ATRS reported a solid 3Q17; however the focus remains squarely on XYOSTED and other pipeline developments.
... MoreAntares Pharma (ATRS) Reports In-Line Q3 EPS
November 7, 2017 7:03 AM ESTAntares Pharma (NASDAQ: ATRS) reported Q3 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $15.1 million versus the consensus estimate of $13.96 million.
For earnings history and earnings-related data on Antares Pharma (ATRS) click here.
... More